Roivant Sciences
ROIV
181 hedge funds and large institutions have $5.02B invested in Roivant Sciences in 2023 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 58 increasing their positions, 46 reducing their positions, and 23 closing their positions.
483% more call options, than puts
Call options by funds: $8.47M | Put options by funds: $1.45M
152% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 23
48% more capital invested
Capital invested by funds: $3.39B → $5.02B (+$1.63B)
26% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 46
23% more funds holding
Funds holding: 147 → 181 (+34)
4.33% more ownership
Funds ownership: 60.57% → 64.9% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$87.8M |
| 2 |
BlackRock
New York
|
+$55.2M |
| 3 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$52M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$51.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$116M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$33.9M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$18.5M |
| 4 |
Goldman Sachs
New York
|
-$15M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LC
201
Lindbrook Capital
Calabasas,
California
| – | -$635 | -86 | Closed |
|
202
US Bancorp
Minneapolis,
Minnesota
| – | -$583 | -79 | Closed |
|
|
EC
203
Elequin Capital
New York
| – | -$7 | -1 | Closed |
|
|
C
204
Covestor
London,
United Kingdom
| – | +$45 | +5 | New |
|
ROIV Hedge Fund Activity: Q2 2023 in Review
181 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q2 2023, worth a combined $5.02B — up 48% from $3.39B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new ROIV positions and 23 closed out — a net gain of 35 holders — while 58 added to existing stakes and 46 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $87.8M. The largest seller was Viking Global Investors, cutting an estimated $116M.
- 181 institutional investors held Roivant Sciences (ROIV) as of Q2 2023, up from 147 in Q1 2023.
- Funds reported $5.02B of Roivant Sciences stock for Q2 2023, up 48% quarter-over-quarter.
- 58 funds opened new Roivant Sciences positions in Q2 2023 and 23 closed out, a net change of +35 holders.
- The largest Roivant Sciences buyer in Q2 2023 was Morgan Stanley, an estimated $87.8M added.
- The largest Roivant Sciences seller in Q2 2023 was Viking Global Investors, an estimated $116M sold.
Based on aggregated 13F filings for Q2 2023.